Study ID: Merck MK7902-006


A Phase 3 Randomized, Placebo-controlled study to evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-Line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)

Title: Experimental treatment of pembrolizumab (also known as Keytruda®) and combination chemotherapy with the addition of either lenvatinib (also known as Lenvima®) or a matching placebo for patients recently diagnosed with metastatic non squamous non small cell lung cancer (NSCLC). Description: Pembrolizumab (MK-3475), also known as Keytruda®, and lenvatinib (MK-7902/E7080), also known as Lenvima®, have been approved by certain health authorities for the treatment of various cancers. However, they may not be approved for your exact type of cancer in your country. The chemotherapy combinations (carboplatin with pemetrexed OR cisplatin with pemetrexed) being used are approved treatments for your type of NSCLC. Getting lenvatinib, pembrolizumab, and combination chemotherapy together is experimental. The purpose is to see how well the study drug controls or stops your type of cancer compared to combination chemotherapy and pembrolizumab without lenvatinib. It is also to see if adding lenvatinib to combination chemotherapy and pembrolizumab helps patients live longer and to further test the safety of the study drug and how your body handles it.
Fargo Region
Principal Investigator:
Amit Panwalkar, MD
Non-Small Cell Lung Cancer
Phase III
Active - Open to Accrual